US 12,077,821 B2
Personalized pain management and anesthesia: preemptive risk identification and therapeutic decision support
Senthilkumar Sadhasivam, Mason, OH (US); Vidya Chidambaran, Cincinnati, OH (US); John McAuliffe, Cincinnati, OH (US); Kejian Zhang, Cincinnati, OH (US); Jaroslaw Meller, Cincinnati, OH (US); Cynthia A. Prows, Cincinnati, OH (US); and Tsuyoshi Fukuda, Cincinnati, OH (US)
Assigned to Children's Hospital Medical Center
Filed by CHILDREN'S HOSPITAL MEDICAL CENTER, Cincinnati, OH (US)
Filed on Jun. 19, 2020, as Appl. No. 16/946,399.
Application 16/946,399 is a continuation of application No. 16/850,537, filed on Apr. 16, 2020.
Application 16/850,537 is a continuation of application No. 15/915,581, filed on Mar. 8, 2018, granted, now 10,662,476, issued on May 26, 2020.
Application 15/915,581 is a continuation of application No. 14/361,946, granted, now 9,944,985, issued on Apr. 17, 2018, previously published as PCT/US2012/067111, filed on Nov. 29, 2012.
Claims priority of provisional application 61/661,073, filed on Jun. 18, 2012.
Claims priority of provisional application 61/565,400, filed on Nov. 30, 2011.
Prior Publication US 2020/0318194 A1, Oct. 8, 2020
Int. Cl. C12Q 1/68 (2018.01); C07H 21/04 (2006.01); C12Q 1/6883 (2018.01); C12Q 1/6806 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 1/6806 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/172 (2013.01)] 5 Claims
 
1. A method for treating a human patient for post-operative pain, the method comprising the steps of
a) obtaining a biological sample from a patient in need of treatment for post-operative pain, wherein the biological sample is obtained prior to administering an opioid analgesic to the patient,
b) genotyping the biological sample from the patient to determine the patient's haplotype at four single nucleotide polymorphisms (SNPs) of the organic cation transporter 1 (OCT1) gene identified by rs12208357, rs34130495, rs72552763, and rs34059508, wherein the genotyping is performed using one or more of a PCR-based technique for nucleic acid amplification from the sample, gel electrophoresis, mass spectrometry, and microarray hybridization,
c) assigning an OCT1 haplotype of *1, *2, *3, *4, or *5 based on the patient's genotype at each of the four SNPs as follows
 
 
rs12208357 rs34130495 rs72552763 rs34059508
 
286C > T 1306G > A 1365GAT > del 1498G > C
 
*1 Arg Gly Met Gly
*2 Arg Gly del Gly
*3 Cys Gly Met Gly
*4 Arg Ser Met Gly
*5 Arg Gly del Arg
 
assigning the patient to Group 0, 1, or 2 based on the patient's haplotype as follows:
Group 0: *1/*1
Group 1: *1/*2, *1/*3, *1/*4, or *1/*5
Group 2: *2/*2, *2/*3, *2/*4, *2/*5, *3/*3, *3/*4, *3/*5, *4/*4, *4/*5, or *5/*5, and
d) administering fentanyl, hydromorphone, codeine, oxycodone, hydrocodone, tramadol, ondansetron, dexamethasone, methadone, alfentanil, remifentanil, acetaminophen, a non-steroidal anti-inflammatory drug (NSAID), dexmedetomidine, or clonidine, to the patient assigned to Group 2 in step c), or
e) administering morphine to the patient assigned to Group 0 or 1 in step c).